Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4

By Shuang Qin, Linping Xu, Ming Yi, Shengnan Yu, Kongming Wu, S. Luo. Molecular Cancer, 2019

991 citations recorded by the source corpus.

The emergence of immune checkpoint inhibitors (ICIs), mainly including anti-programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) and anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) monoclonal antibodies (mAbs), has shaped therapeutic landscape of some type of cancers. Despite some ICIs have manifested compelling clinical effectiveness in certain tumor types, the majority of patients still showed de novo or adaptive resistance. At present, the overall efficiency of immune checkpoint therapy remains unsatisfactory. Exploring additional immune checkpoint molecules is a hot research topic. Recent studies have identified several new immune checkpoint targets, like lymphocyte activation gene-3 (LAG-3), T cell immunoglobulin and mucin-domain containing-3 (TIM-3), T cell immunoglobulin and ITIM domain (TIGIT), V-domain Ig suppressor of T cell activation (VISTA), and so on. The investigations about these molecules have generated promising results in preclinical studies and/or clinical trials. In this review, we discussed the structure and expression of these newly-characterized immune checkpoints molecules, presented the current progress and understanding of them. Moreover, we summarized the clinical data pertinent to these recent immune checkpoint molecules as well as their application prospects.

Subfields: Oncology

View Paper: https://www.semanticscholar.org/paper/60300da0bda8f1be17af421b517730178ff18cc6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

  1. Y. Shiravand
  2. R. Ladwa
  3. K. O'Byrne
  4. S. R. Hosseini-Fard
  5. Faezeh Khodadadi
  6. Seyyed Mohammad Amin Kashani
  7. H. Sadeghirad
  8. Shadi Hosseini

Citations in the corpus